应北京大学“大学堂”顶尖学者讲学计划的邀请,国际知名的生物物理学家、生物工程学家、美国科学院院士斯蒂芬•奎克教授将于2018年11月6日访问北京大学,并发表公开演讲。 Stephen Quake 题目:The cell is a bag of RNA 时间:2018年11月6日(周二)15:00-17:00 地点:北京大学金光生命科学大楼101报告厅 斯蒂芬·奎克(Stephen Quake) ,生于1969年4月,是国际著名的生物物理学家、生物工程学家,是国际基因组学领域的重要领导者之一。他是美国国家科学院院士、美国国家工程院院士、美国国家医学院院士,美国艺术与科学学院院士。他曾担任斯坦福大学生物工程系主任,现任斯坦福大学生物工程Lee Otterson讲席教授和应用物理学教授,并担任由扎克伯格基金会投资建设的BioHub研究中心联席总裁。 奎克教授于1994年在牛津大学获得物理学博士学位,随后,他在斯坦福大学朱棣文课题组从事单分子生物物理学的博士后研究工作。26岁时他加入了加州理工学院任教,后被任命为Thomas和Doris Everhart应用物理和物理学教授。2005年奎克教授回到斯坦福大学,建立了一个新的生物工程系,担任教授,同时入选霍华德休斯医学研究所。 奎克教授在微流控领域做出了杰出贡献,包括其发明的微流体大规模集成设计并将微流控技术广泛应用于结构生物学,药物发现和分子亲和力测量中;同时他还为基因组学领域做出了贡献,包括单分子DNA测序,并将其用于非侵入性产前诊断和心脏的非侵入性测试移植排斥,以及开发测序和分析个体免疫系统的方法等。 Stephen Quake is the Lee Otterson Professor of Bioengineering and Professor of AppliedPhysics at Stanford University and is co-President of the Chan Zuckerberg Biohub. He received a B.S. in Physics and M.S. in Mathematics from Stanford University in 1991 and a doctorate in Theoretical Physics from the University of Oxford in 1994. Quake has invented many measurement tools for biology, including new DNA sequencing technologies that have enabled rapid analysis of the human genome and microfluidic automation that allows scientists to efficiently isolate individual cells and decipher their genetic code. Quake is also well known for inventing new diagnostic tools, including the first non-invasive prenatal test for Down syndrome and other aneuploidies. His test is rapidly replacing risky invasive approaches such as amniocentesis, and millions of women each year now benefit from this approach. His innovations have helped to radically accelerate the pace of biology and have made medicine safer by replacing invasive biopsies with simple blood tests. 主办单位:北京大学 承办单位:北京大学生物医学前沿创新中心 北京未来基因诊断高精尖创新中心 北京大学国际合作部 “大学堂”顶尖学者讲学计划网站: www.pugf.pku.edu.cn
文章来源:麦姆斯咨询 原文链接: http://www.mems.me/mems/microfluidics_201609/3473.html POINT-OF-NEED TESTING: APPLICATION OF MICROFLUIDIC TECHNOLOGIES 购买该报告请联系: 麦姆斯咨询 吴越 电子邮箱:wuyue#memsconsulting.com(#换成@) 应用于人类和动物体外诊断的分散检验越来越多地采用创新的微流控技术。 很多应用开始受益于微流控技术,但是还没有充分发挥其潜力 即时诊断(Point-of-Care Testing, PoCT)已经不是一个新概念了——首次应用出现于20世纪90年代。此后,微流控技术越来越多地被用来解决生物医疗领域的诊断技术问题,并产生重要的经济价值。在过去几年中,一些应用已经从技术改进中获益,如兽医诊断、环境检测、农副产品和工业检测等。在上述应用中,分散检验(Decentralized Testing)带来显著的运营优势,而微流控技术是生物医疗检验或诊断革命的一部分,促使相关产品在市场上爆发增长。然而,目前还有不少应用没有或很少采用微流控解决方案,因此微流控技术的潜力还没有充分发挥。 在本报告中,我们分析了为何人类医疗保健市场对技术研发人员富有更大的吸引力。然而,在不久的将来,巨大的微流控机遇将浮现在各种应用市场中。本报告还探讨了分散检验/即时需求诊断(Point-of-Need Testing, PoNT)需要解决的技术障碍。基于微流控的即时需求诊断市场将从2015年的26亿美元增长到2021年103亿美元,复合年增长率为26%。这预示2021年将有超过5亿次的诊断测试,但是人体诊断以外的应用仅有6100万次。我们在报告中详细介绍了微流控技术在每一种应用中的发展演进。 即时需求诊断市场(包括微流控技术和其它技术) 技术突破正在改变即时需求诊断 自从即时诊断的出现,技术一直在不断改进,但是诊断公司和技术研发人员仍然在努力整合微流控芯片的复杂检验步骤,并使其自动化。这些复杂的检验通常涉及分子分析,因此需要操作者的人工干预,以完成样品准备或操作笨重的仪器设备。然而,2015年是行业的重大转折点:美国食品和药物管理局(FDA)根据临床实验室改进修正案(CLIA)授权了首个豁免资格,许可了一款基于DNA/RNA的诊断试剂——Alere i 流感 AB。此前,这款试剂仅用于某些实验室,而现在可被分销到各种非传统实验室地点,包括医师办公室、急救室、卫生部门诊所及其它卫生保健场所。随后,Alere i Strep A、罗氏Cobas LIAT Strep A、Flu AB和Flu/RSV、Cepheid公司 GeneXpert Flu/RSV Xpress陆续获得豁免资格。我们预计,未来将有更多基于微流控的诊断技术获得FDA的豁免资格,进而使得分子即时需求诊断迅速蔓延至其它应用领域。 我们也进入了一个医疗转型期,未来将在医院、诊所和医生办公室通过即时诊断技术实现季节性疾病的分子诊断,如流感。基于聚合酶链反应(PCR)的诊断比免疫诊断敏感很多,并能够区分同一疾病的菌株。随着愈来愈多的公司涉足分子诊断,并且逐步取得良好的进展,未来的前景是可期待的。本报告中,我们详细介绍了这些最新的技术进展,包括样品制备、PCR集成或等温扩增技术,这些将打开基于微流控技术的分散检验之门。 即时诊断中的规则改变者 即时诊断的优势凸显,正推动个性化医疗发展 更快、更便宜、更易于使用:微流控技术已经改变了即时诊断。如今,即时诊断已经从医院扩展至医生办公室、病患家中,甚至是在发展中国家的偏远地区。这使得早期诊断、临床决策和更精确的病情监测成为可能。这种对于预防和早期发现疾病的医疗实践转变,结合伴随诊断(companion diagnostics)的爆发,将最终带来重大转变,使得个性化医疗成为现实。 应用于即时需求诊断的微流控技术发展路线图 新一代诊断测试技术将帮助医生确定哪种药物剂量对哪些病人的治疗效果最好。因此,可以提高整体治疗效果,降低医疗成本。虽然政府在医疗转变方面略显“迟钝”,但即时诊断发展趋势现在是大家公认的。最近,欧洲和中国也在监管法规方面做出新的改变。本报告介绍了美国、欧洲和中国的即时需求诊断应用情况,包括监管法规、市场准入门槛、主要厂商等。 本报告涉及的公司: Abaxis, Abbott Point of Care, Accriva Diagnostics, Achira, AgPlus Diagnostics, Akonni Biosystems, Alere (Abbott), Ativa Medical, Atlas Genetics, Atonomics, BD Diagnostics, BioCartis, Biodetection Instruments, Biofre (bioMérieux), BioSensia, Biosurft, Carbo Analytics, Carclo Diagnostic Solutions, Cepheid, Coris BioConcept, Daktari Diagnostics, DNA electronics, Dolomite Microfluidics, Enigma Diagnostics, Etta Healthcare (OvaGene Oncology), Fast-track Diagnostics, F Cubed, FluimediX, Focus diagnostics (DiaSorin Group), Genalyte, GeneFluidics, GenePOC, Great Basin, HemoCue (Radiometer, Danaher), Ikerlan, INO, Instant Labs, Iquum (Roche), Lacrisciences, LeukoDx, Luminex, Medimate, Mesa Biotech, Micronics (Sony), Molbio Diagnostics Pvt. Ltd, Nanomix, Nanosphere, NetBio, OndaVia, OPKO Diagnostics, Oxford Nanopore, Pall Corporation, PathSensors, Patterson, Philips, POC Medical Systems, PositiveID, QuantuMDx, Radiometer (Danaher), Radisens Diagnostics, Rheonix, Roche, Samsung, Sandstone Diagnostics, Sanwa Biotech, Schlumberger, SMB (Zoetis), Sony DADC (Stratec), Spartan Bioscience, Sphere Medical, SpinChip Diagnostics AS, StableLab, STMicroelectronics, TearLab, Tecil, Ubiquitome, Vista Therapeutics, Wako Diagnostics等。 报告目录: Executive summary Introduction What happened since 2014? Merger and acquisition analysis Collaborations Fundraising New products launched on the market PoN statistical analysis including applications covered and type of sample used Market data and forecasts Our defnitions and market segmentation Point of need test market data and forecast in volume Point of need test market data and forecast in value Related microfluidic device market for point of need testing in volume and value Microfluidics contribution in the fnal selling price of a test Microfluidic-based PoN tests market growth by segment Market segmentation Methodology Segment descriptions - S1: Emergency testing - S2: Third-world infections: remote area testing - S3: Home tests, doctor’s offce screening, decentralized hospital tests - S4: Genetic testing, companion diagnostics, forensics - S5: Veterinary testing - S6: Environmental and industrial testing - S7:Agro-food testing Focus on molecular diagnostics Sample preparation challenges Who’s the next PoC giant? Assay menus and multiplexing Which company is providing which assay menu? Focus on cardiac biomarkers High-plex vs. low-plex Regulatory and market access for Point-of-Care testing Regulatory requirement by country for USA, Europe and China Focus on the new IVD directive arriving in Europe Reimbursement landscape for Point-of-Care testing Reimbursement landscape in USA Reimbursement landscape in France, Germany, UK Regulations for veterinary diagnostics Regulations for agro-food industry Supply chain Conclusions 若需要《即时需求诊断:微流控技术应用》报告样刊,请发E-mail:wuyue#memsconsulting.com(#换成@)。
Blood plasma separation microfluidic chip with gradual filtration Jingdong Chen , Di Chen, Tao Yuan, Xiang Chen, Yao Xie, Hualin Fu,Daxiang Cui, Xudong Fan, Maung Kyaw Khaing Oo Blood plasma separation microfluidic chip with gradual filtration.pdf Blood is one of the most crucial biological materials that can be used to diagnose diseases. In order to avoid the effects of blood cells for cell free plasma detection, the first step toward a blood test is the blood separation. We developed a microfluidic chip for blood plasma separation with gradual filtration, which consisted of front-end cell capture structures and back-end filters. Two types of filters were proposed: straight line filters and square wave filters. The cell capture structures and filters, fabricated on PDMS (polydimethylsiloxane), included two structural layers. The first layer consisted of pillars to create small gaps between the second layer and glass, which enabled the flow of the plasma through the capture structures while trapping the cells in the structures. The second layer was an array of U-shaped structures. The results showed that the separation efficiency of plasma enhanced with increased dilution factor and decreased height of the gap created by the pillar layer. The separation efficiency was only 20% under 2 lm gap and dilution factor 10 and increased to 91% under the gap of 1 lm height and dilution factor 50 in the chip with the straight line filters. The separation efficiency was close to 100% under the gap of 1 lm height and dilution factor 20 in the chip with the square wave filters. Blood plasma separation microfluidic chip with gradual filtration.pdf